e-learning
resources
London 2016
Tuesday, 06.09.2016
Novel avenues in the treatment of COPD II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Medication adherence in high exacerbation risk groups of COPD
Esra Uzaslan (Bursa, Turkey), Esra Uzaslan, Nilüfer Aylin Acet Öztürk, Asli Görek Dilektasli, Ezgi Demirdögen Çetinoglu, Funda Coskun, Ahmet Ursavas, Mehmet Karadag
Source:
International Congress 2016 – Novel avenues in the treatment of COPD II
Session:
Novel avenues in the treatment of COPD II
Session type:
Thematic Poster
Number:
4079
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Esra Uzaslan (Bursa, Turkey), Esra Uzaslan, Nilüfer Aylin Acet Öztürk, Asli Görek Dilektasli, Ezgi Demirdögen Çetinoglu, Funda Coskun, Ahmet Ursavas, Mehmet Karadag. Medication adherence in high exacerbation risk groups of COPD. Eur Respir J 2016; 48: Suppl. 60, 4079
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
COPD on anti-GERD therapy remains at higher risk for severe exacerbation
Source: International Congress 2014 – COPD exacerbations
Year: 2014
The relation of comorbidities with the exacerbation severity in patients with COPD
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Comparison of COPD patients with high and low symptoms from a real-world US survey
Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases
Year: 2015
High risk COPD patients cost less if treated according to GOLD 2011 recommendations
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013
COPD patients with asthma, characteristics and risk of exacerbations
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019
Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
Risk factors for another hospitalization in COPD patients hospitalized for exacerbation
Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases
Year: 2016
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015
Frequency of COPD exacerbations and severity of COPD
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
The impact of comorbidities on the short-term serious health outcomes in hospitalized COPD patients due to exacerbation
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
COPD: Influence of patients’ nutritive status on the exacerbations rate
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
Gender differences in hospitalized patients with acute exacerbation of COPD
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
Association of COPD inhaled medication adherence with hospitalization for acute exacerbation of COPD (AECOPD)
Source: International Congress 2017 – COPD management
Year: 2017
Recording and response to hyperglycaemia in patients presenting with infective exacerbations of COPD
Source: Annual Congress 2013 –Difficult and rare respiratory infections
Year: 2013
Symptom profile of exacerbations in earlier and later COPD
Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes
Year: 2013
COPD exacerbations and predictors in a general population
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016
Comparing the prevalence of depression and anxiety in patients admitted with an exacerbation of COPD using two scoring systems
Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations
Year: 2015
Baseline symptom scores and future risk of severe exacerbation: The SPARK study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept